Meeting
2016 Genitourinary Cancers Symposium
Randomized phase I/II trial of two schedules of bortezomib and bevacizumab (BBmibmab) in metastatic renal cell cancer: USC trial 4K-05-1.
Authors
David I. Quinn
USC Norris Comprehensive Cancer Center, Los Angeles, CA
David I. Quinn , Denice Wei , Kristy Massopust , Charlean Ketchens , James Hu , Amir Goldkorn , Ana Aparicio , Sarmad Sadeghi , Jacek K. Pinski , Monica Averia , Susan G. Groshen , Tanya B. Dorff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT00184015
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 574)
DOI
10.1200/jco.2016.34.2_suppl.574
Abstract #
574
Poster Bd #
G13
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.
First Author: Roberto Pili
Poster
2023 ASCO Annual Meeting
Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.
First Author: Joseph Allan Norton
Poster
2022 ASCO Genitourinary Cancers Symposium
Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.
First Author: Omar Alhalabi
Poster
2019 Genitourinary Cancers Symposium
A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
First Author: Saby George